Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1493MR)

This product GTTS-WQ1493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2497MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ14859MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ829MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ2364MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ7376MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ2688MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ9807MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ3951MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW